Candida bloodstream infection (BSI) remains one of the leading causes of BSI in critically ill and immunosuppressed cancer patients. In light of the changing epidemiology and rising resistant species, duration of treatment and appropriate timing of stepdown therapy from intravenous (IV) to oral antifungal agents are crucial for utmost disease control and overall survival.

中文翻译：

---

非中性粒细胞减少患者念珠菌血症降级治疗的时机：一项国际多中心研究。

念珠菌血流感染 (BSI) 仍然是重症和免疫抑制癌症患者发生 BSI 的主要原因之一。鉴于不断变化的流行病学和耐药物种的增加，治疗持续时间和从静脉内 (IV) 到口服抗真菌药物的降级治疗的适当时机对于最大限度地控制疾病和总体生存至关重要。